专题：2025基金行业年终大盘点：公募规模近36万亿元，主动权益重夺主场，"冠军基"揭榜倒计时 文|吴理想 来源|财富独角兽 2025年股市征战即将结束，主动权益类公募基金年终排行榜即将呈现，在冠军基金早 早失去悬念的同时，谁将不幸成为年终倒数第一也备受关注，目前看最有可能的倒霉蛋是次新基金华富 医疗创新。 截止12月26日收盘，该基金在年内的最新净值仅仅约为0.7665元，产品自成立以来净值下跌约为 23.35%。从产品近一周、近一月、近三月的同类排名来看，其均排在同类大约5000只产品中较为靠后 的位置。该基金的基金经理廖庆阳目前还管理着华富健康文娱灵活配置混合，但该基金今年大约25%的 净值增长率不温不火，仅仅排在同类中游的位置。同时，这位任职已满4年的基金经理，三季度末时管 理基金资产的总规模仅仅约为2.76亿元，在管基金的最佳任期回报约为10.34%。 对照来看该基金对标的指数，同期其明显要大幅弱于中证医药的走势，或许说明了其投资风格发生了一 定偏离。诚然，以创新药为首的医药股在8月以后完全没了行情，但该基金更弱的表现或许还因为基金 经理快速建仓所导致。目前，产品还没有正式对外披露过一份财报。 不过 ...

12月25日，山西省人民医院与华为技术有限公司合作协议签约仪式在山西省人民医院会议中心举行。华 为山西政企业务部总经理帅军超、山西省人民医院院长田首元出席会议并致辞，山西省人民医院副院长 石晶主持会议。华为山西政企Marketing与解决方案销售部、华为山西政企医疗业务部负责人及山西省 人民医院相关职能部门负责人参会并见证签约。 田首元院长在讲话中指出，此次战略合作将充分整合双方优势资源，深度推进"技术+场景"的融合应 用，共同研发适合我省发展需求、具备可复制性和推广性的数智医疗解决方案，致力于打造全国领先的 智慧医院示范项目，引领智慧医疗建设迈向新的发展阶段。 随后，田首元院长与帅军超总经理代表双方签署合作协议。本次合作将重点围绕医疗+人工智能、健康 医疗大数据、医疗大数据科研平台、数字化基础设施、一院多区统一数字化平台、基于数据流共享模式 的医联体远程会诊等领域展开，加速人工智能与大数据技术在医疗健康领域的创新应用。 此次合作协议的签署，标志着山西省人民医院与华为的合作迈入了以科技创新驱动医疗变革的战略新阶 段。未来，双方将凭借各自优势推动AI应用场景创新，共享技术带来的效率提升与服务优化红利，为 构建山 ...

本文源自：市场资讯 作者：公告君 回购日期回购均价回购股数回购金额本年累计回购股数2025-12-185.12819.00万97.44万723.13万2025-12- 174.98140.00万199.23万704.13万2025-12-164.94464.08万316.83万664.13万2025-12-125.10115.50万79.07 万600.05万2025-12-115.01253.50万268.16万584.55万2025-12-095.15134.50万177.70万531.05万2025-12- 085.23722.50万117.82万496.55万2025-12-055.18328.00万145.12万474.05万2025-12-045.14718.10万93.16 万446.05万2025-12-035.09039.20万199.53万427.95万2025-10-245.6462.12万11.97万388.75万2025-10- 235.54335.00万194.02万386.63万2025-10-225.6391.77万9.98万351.63万2025-10-215.7015.96 ...

Core Points - The launch of the national medical insurance imaging cloud for cross-province retrieval marks a significant advancement in medical imaging services, allowing for seamless access to patient imaging data across different regions [1][2][3] - The initiative aims to enhance diagnostic accuracy and efficiency by overcoming traditional barriers associated with physical film storage and retrieval, thus facilitating better patient care [2][3][4] Group 1: Technological Advancements - The transition from traditional film to cloud-based imaging solutions addresses the limitations of physical films, such as their bulkiness, susceptibility to damage, and inability to capture detailed images [2][3] - The national medical insurance imaging cloud has indexed over 170 million imaging records, with a goal to establish a "national network" by 2027 [3] Group 2: Operational Efficiency - The implementation of a unified platform and indexing standards allows for efficient storage and retrieval of imaging data, significantly reducing costs associated with data transmission [3] - The cloud service is priced at 5 yuan per person per imaging instance, promoting local storage and cross-regional transmission as a medical service [3] Group 3: Patient-Centric Care - Patients can now access, download, and share their imaging data without incurring additional fees, which enhances the convenience of tiered medical services and remote consultations [3][4] - The ability to consult with high-level medical institutions remotely improves diagnostic quality and resource utilization across the healthcare system [4][5] Group 4: Future Innovations - The data generated from imaging services is expected to drive innovations in AI-assisted diagnostics and remote medical applications, further benefiting patients and healthcare professionals [4]

Summary of the Conference Call for Yidu Technology Industry Overview - National policies and local government support are accelerating the commercialization of AI in healthcare, particularly in ICU settings, where AI-assisted diagnosis has been included in medical service pricing projects, promoting the development of medical AI [2][4] - There is a significant difference in the application of AI in drug development versus diagnostic services, with diagnostic services advancing more rapidly and already being applied in pre-diagnosis, diagnosis, and post-diagnosis stages, enhancing efficiency and accuracy [2][5] Company Insights - Yidu Technology's main business includes big data platforms and solutions (for hospitals and regulatory agencies), life sciences solutions (for pharmaceutical companies), and health management platforms (for public health insurance), having served numerous top hospitals and pharmaceutical clients [2][10] - The company has connected its DeepSeek technology to 420 hospitals, with over 50% being top-tier hospitals [6] - Yidu Technology has launched a hardware-software integrated AI platform, compatible with mainstream chips and open-source large models, which has been implemented in over 20 hospitals and is expected to boost revenue [3][16] Financial Performance and Projections - The company operates on a fiscal year ending March 31, with expectations to break even in fiscal year 2026 or 2027, driven primarily by the big data platform [3][17] - The gross margin remains stable at around 40%, with good expense control, but the company has not yet achieved profitability [17] - The big data platform and solutions are expected to be the main growth drivers, while life sciences solutions are projected to recover in fiscal years 2026 to 2027 [18] Key Business Metrics - The big data platform has covered 2,800 hospitals and accumulated over 800 specialized disease databases, serving more than 40 health commission agencies [11] - The life sciences solutions segment serves 71 pharmaceutical companies, with a retention rate exceeding 100% for top clients [12] - The health management platform has reached 24 million users, providing a solid customer base for future C-end business development [14] AI Technology Impact - The company has processed and analyzed data from over 1.1 billion patient visits and 5.5 billion authorized medical records, ranking first in specific scenarios such as medical knowledge Q&A and medical language understanding [15] - The integration of DeepSeek into its framework and partnerships with major companies like Huawei and ByteDance help maintain industry leadership and expand the product ecosystem [15] Valuation and Target Price - The initial coverage uses a price-to-sales (PS) valuation method, with a target price of HKD 77 per share, based on a PS ratio of 77.7, and a buy rating assigned [19]